Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

Moderna said mFLUSIVA is now its fifth approved product globally and fourth that is FDA-approved. The company expects supply to be available in select retailers over the coming weeks, signaling continued commercial progress rather than a major fundamental shift.

Analysis

Moderna said mFLUSIVA is now its fifth approved product globally and fourth that is FDA-approved. The company expects supply to be available in select retailers over the coming weeks, signaling continued commercial progress rather than a major fundamental shift.